PF-07104091 monotherapy dose escalation

PF-07104091 will be administered orally in combination with palbociclib and fulvestrant

PF-07104091 + palbociclib + fulvestrant

PF-07104091 will be administered orally in combination with palbociclib and letrozole

PF-07104091 + palbociclib + letrozole

PF-07104091 monotherapy dose expansion (SCLC)

PF-07104091 monotherapy dose expansion (ovarian)

PF-07104091 + fulvestrant (post CDK4/6) dose expansion

PF-07104091 + fulvestrant (post 4/6) dose expansion

PF-0704091 + Fulvestrant (post CDK4/6)

CDK2+ fulvestrant (post CDK 4/6) dose escalation

PF-07104091 will be administered orally in combination with fulvestrant

PF-07104091 + Fulvestrant (post CDK4/6)

Daily Compound Ciwujia granules+ standard treatment protocol for ovarian cancer+ psychological intervention

In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, Compound Ciwujia Granules were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.

Compound Ciwujia Granules

Standard treatment protocol for ovarian cancer: In accordance with the 2024 NCCN International Guidelines, patients opt for chemotherapy regimens containing platinum-based drugs and/or targeted therapy, anti-angiogenic therapy, hormonal therapy, etc. Psychological intervention is conducted once a week in the form of online and offline patient education sessions for psychological intervention, continuing until the end of the study period. Both the intervention group and the control group use this as the baseline treatment plan.

Standard treatment protocol for ovarian cancer combined with psychological intervention.

Daily placebo granules + standard treatment protocol for ovarian cancer+ psychological intervention

In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, placebo granules which containing 10% of Compound Ciwujia Granules drug were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.

Placebo granules

Shanghai Municipal Hospital of Traditional Chinese Medicine

Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk prediction

Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk for all women (including trans-men, and non-binary individuals with female reproductive organs) over the age of 18 years independent of any family or personal history of cancer.

Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk

Women, trans men, and non-binary people with female reproductive organs who are ≥18 years at consent

+ 팔보시클립 + 풀베스트란트, PF-07104091 + 팔보시클립 + 레트로졸, PF-07104091 단독 요법 용량 확장(난소암), PF-07104091 단독 요법 용량 확장(소세포폐암), PF-07104091 + 풀베스트란트(CDK4/6 억제 후), PF-0704091 + 풀베스트란트(CDK4/6 억제 후)

복합 치우지아 과립, 위약 과립, 심리적 개입과 결합된 난소암에 대한 표준 치료 프로토콜.

1C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6)에 대한 유전자 검사 및 개인 맞춤형 유방암 및 난소암 위험도 평가